3-Hydroxypyrazine-2-Carboxamide CAS 55321-99-8 Puritas >98.0% (HPLC) Favipiravir Intermedia COVID-19 Featured Image

3-Hydroxypyrazine-2-Carboxamide CAS 55321-99-8 Puritas >98.0% (HPLC) Favipiravir COVID-19

Description:

Nomen chemicum: 3-Hydroxypyrazine-2-Carboxamide

CAS: 55321-99-8

Aspectus: Lumen Yellow ad Brown pulveris

Puritas: >98.0% (HPLC)

Intermedia Favipiravir (CAS: 259793-96-9) in curatione Influentiae virus et COVID-19

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Commercial Supple Favipiravir et intermedia:
Favipiravir CAS 259793-96-9
2-Aminopropanediamide CAS 62009-47-6
Diethyl Aminomalonatum Hydrochloridum CAS 13433-00-6
3,6-Dichloropyrazinum-2-Carbonitrile CAS 356783-16-9
3,6-Difluoropyrazine-2-Carbonitrile CAS 356783-28-3
6-Fluoro-3-Hydroxypyrazine-2-Carbonitrile CAS 356783-31-8
6-Bromo-3-Hydroxypyrazine-2-Carboxamide CAS, 259793-88-9
3-Hydroxypyrazine-2-Carboxamide CAS 55321-99-8

Chemical Properties:

Nomen chemicum	3-Hydroxypyrazine-2-Carboxamide
Synonyma	T-1105;3-Hydroxy-2-Pyrazinecarboxamide;Favipiravir Desfluoro Impuritas;3-Oxo-3,4-dihydropyrazine-2-carboxamide
CAS Number	55321-99-8
CATTUS Number	RF-PI295
Stock Status	In Stock, Productio Ascendite usque ad chiliogrammata
Formulae hypotheticae	C5H5N3O2
M. Pondus	139.11
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Lux Yellow ut Brown pulveris
Lepidium sativum	IR, HPLC
Damnum in Siccatio	<1.00%
una immunditia	<0.50%
Metalla gravis	≤20ppm
Puritas	>98.0% (HPLC)
Test Standard	Enterprise Standard
Consuetudinem	Favipiravir (CAS, 259793-96-9)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore

commoda:

FAQ:

Applicatio:

3-Hydroxypyrazine-2-Carboxamide (CAS 55321-99-8) est medium seu immunditia Favipiraviri Medii (CAS 259793-96-9).Favipiravir medicamento lato-spectro antivirali novum est.Favipiravir adhiberi potest ad tractationem antiviralem influentiae A et B. Studia monstraverunt praeter virus influenza, medicamentum etiam bonam antiviralem actionem contra varias virus RNA exhibere, sicut virus Ebola, virus arenae, virus Bunia, et rabies. virus.In ingruente novo Coronaviro Morbus 2019 (COVID-19), Favipiravir adhiberi potest in curatione aegrorum cum COVID-19 commendata a WHO.